RxDoctor Payments Data

Truc Dao, MD

Psychiatry · Garden Grove, CANPI 1235185075

Payments from drug & device makers

$4,524in general payments, 2019–2025

Across 70 payments — averaging $64.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$591
  • Alkermes, Inc.$482
  • Otsuka America Pharmaceutical, Inc.$473
  • Gilead$466
  • Teva Pharmaceuticals USA, Inc.$431
  • plus $878 from 7 others

What the payments were for

  • Food & beverage$4,47699%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,524 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$166,969
Medicare patients
191
Services billed
1,201

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate20$66,354
Abilify MaintenaAripiprazole11$28,700
Risperdal ConstaRisperidone Microspheres17$27,094
FanaptIloperidone11$21,644
Seroquel XrQuetiapine Fumarate12$18,105
VraylarCariprazine Hcl12$16,682
Aripiprazole170$15,726
Lurasidone Hcl32$10,292
Trazodone Hcl737$8,996
Mirtazapine620$5,984
Quetiapine Fumarate339$5,942
Olanzapine136$3,781
Clozapine35$2,558
Paliperidone ErPaliperidone18$2,248
Risperidone228$1,842

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$591$93,44837 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$473$28,70011 claims
AbbVieVraylar$1,204$16,68212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →